Table 1.
Cardiovascular baselines after pre-treatment, and the response to pre-treatment below in parenthesis.
| Pre-treatment | WKY | SHR | ||||||
|---|---|---|---|---|---|---|---|---|
| MBP mmHg | HR bpm | CO ml/min | TPR mmHg/ml/min | MBP mmHg | HR bpm | CO ml/min | TPR mmHg/ml/min | |
| PBS | 61±4 | 339±12 | 28±1 | 2.2±0.1 | 89±10* | 388±12** | 31±3 | 2.9±0.2** |
| (−3±2) | (−16±3) | (0±1) | (−0.2±0.0) | (−4±4) | (−11±8) | (2±1) | (−0.3±0.1) | |
| PBS after reserpinea | 64±4† | 361±12 | 27±2 | 2.4±0.1 | ||||
| (−4±2) | (−16±5) | (−1±0) | (−0.1±0.0) | |||||
| Methoctramine+PBS | 60±2 | 366±7 | 31±2 | 2.0±0.1 | 83±6 | 458±11††† | 21±2† | 4.0±0.3†† |
| (−1±2) | (32±12)†† | (3±1) | (−0.3±0.1) | (12±7) | (50±17)†† | (−1±1) | (0.6±0.2)†† | |
| Hexamethonium | 53±2†† | 345±19† | 25±1 | 2.9±0.2 | ||||
| (−33±7)†† | (−67±8)††† | (−1±1) | (−1.4±0.2)†† | |||||
| XE-991 | 48±3† | 290±22 | 32±6 | 1.8±0.3 | 65±3† | 384±13 | 24±1 | 2.8±0.2 |
| (−7±5) | (−43±24) | (5±3) | (−0.4±0.2) | (−14±5) | (−21±15) | (2±1) | (−0.8±0.2) | |
| XE-991 after reserpinea | 61±4† | 340±10† | 31±1 | 2.0±0.1†† | ||||
| (−12±3) | (−41±12) | (4±1) | (−0.7±0.1) | |||||
| Methoctramine+XE-991 | 66±8 | 442±8†† | 21±2† | 3.2±0.2 | ||||
| (−16±7) | (50±6)††† | (0±1) | (−0.8±0.5) | |||||
| Hexamethonium+XE-991 | 49±3†† | 334±10†† | 16±2†† | 3.2±0.2 | ||||
| (−43±5)††† | (−71±13)†† | (−2±1)† | (0.4±2.5) | |||||
| Chromanol 293B | 68±4 | 340±14 | 30±2 | 2.4±0.2 | 65±9 | 369±11 | 17±2†† | 3.8±0.3† |
| (−4±1) | (−2±5)† | (2±1) | (−0.3±0.1) | (−14±5) | (−21±7) | (−2±0)† | (−0.4±0.2) | |
| Retigabine | 53±3 | 310±17 | 36±2†† | 1.5±0.1††† | 64±6 | 363±10 | 22±1† | 3.2±0.3 |
| (−2±3) | (−5±4)† | (4±1)† | (−0.2±0.1) | (−8±2) | (−23±10)† | (2±0) | (−0.3±0.3) | |
| Retigabine after reserpinea | 63±4† | 354±6† | 28±2 | 2.3±0.2† | ||||
| (−9±1) | (−23±4) | (1±1) | (−0.4±0.1) | |||||
| ICA-27243 | 61±5† | 377±5 | 19±1††† | 3.3±0.2 | ||||
| (−3±5) | (−31±8) | (0±0) | (−0.1±0.2) | |||||
| ICA-27243 after reserpinea | 75±5 | 349±8† | 26±2 | 2.9±0.2 | ||||
| (−1±3) | (−25±6) | (0±1) | (−0.1±0.1) | |||||
a
Reserpine was administered prior to the experiment, and the effect of reserpine combined with PBS, XE-991, retigabine or IC-27243 are therefore indicated by the differences in baselines prior to 3,4-DAP, whereas the response to PBS, XE-991 or retigabine in reserpinized SHR are shown in parenthesis below. Significant differences between the WKY and SHR control groups (*), between corresponding control and experimental groups (†) were detected as indicated.
*,†
P ≤ 0.05,
**,††
P ≤ 0.01, and
†††
P ≤ 0.001.